KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Key facts

Sponsor

Kyowa Kirin, Inc.

Principal Investigator

Michael Kurman, MD

Kyowa Hakko Kirin Pharma, Inc.

Intervention

KW-0761(biological)

Enrollment

71 enrolled

Eligibility

18 years · All sexes

Timeline

2012 – 2018

Study locations (20)

• Cedars-Sinai Medical Center, Los Angeles, California, United States
• University of Miami / Sylvester Comprehensive Cancer Center, Miami, Florida, United States
• Northwestern University, Chicago, Illinois, United States
• National Cancer Institute, Bethesda, Maryland, United States
• Washington University School of Medicine, St Louis, Missouri, United States
• Hackensack University Medical Center, Hackensack, New Jersey, United States
• Memorial Sloan Kettering, New York, New York, United States
• Columbia Presbyterian, New York, New York, United States
• Weill Cornell Medical College, New York, New York, United States
• Montefiore Medical Center, The Bronx, New York, United States
• Cliniques Universitaires Saint-Luc, Brussels, Belgium
• Hospital Universitario Professor Edgard Santos- UFBA, Salvador, Bahia, Brazil
• Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo- SP, Brazil
• CHU de Fort de France, Fort de France Cedex, France
• Hospital Necker, Paris, France
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult T-cell leukemia/lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT05745714
  HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
  Princess Maxima Center for Pediatric Oncology
• RECRUITINGPHASE2NCT07159620
  Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
  The First Affiliated Hospital of Soochow University
• RECRUITINGNCT05237986
  Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
  National Cancer Institute (NCI)
• RECRUITINGPHASE1NCT07108868
  A Phase I Dose Finding Study of MB-CART2219.1
  University Hospital Tuebingen
• RECRUITINGPHASE1, PHASE2NCT07008885
  BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
  Chinese PLA General Hospital
• ACTIVE NOT RECRUITINGPHASE3NCT07541755
  PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL
  Fujian Medical University Union Hospital
• RECRUITINGPHASE2NCT06698003
  A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
  Memorial Sloan Kettering Cancer Center
• RECRUITINGPHASE2NCT06598722
  BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

See all trials for Adult T-cell leukemia/lymphoma →